Indeed, our results are concordant with previously reported findings by Yang et al, where RFA combined with liposomal paclitaxel (an apoptosis enhancer) resulted in greater apoptosis (as measured by caspase 3), yet did not suppress tumor growth to a similar extent as liposomal doxorubicin [13]. The gene discussed is CASP3; the disease is neoplasm.